Although cigarette smoking is known to be an important risk factor for renal disease, the mechanism by which smoking induces progressive renal disease in a healthy population has not been established. We hypothesized that oxidative stress (measured as 8-iso-prostaglandin F 2a , 8-iso-PGF2a), inflammation (highly sensitive C-reactive protein (CRP), hs-CRP) and nitric oxide may be associated with an alteration in the estimated glomerular filtration rate (eGFR) and proteinuria in otherwise healthy smokers. A total of 649 eligible subjects were classified according to their smoking status. Plasma NOx was measured using ozone-based chemiluminescence, urinary 8-iso-PGF2a was measured using enzyme immunoassay and serum hs-CRP was measured using a latex aggregation nephelometry method. The levels of 8-iso-PGF2a and hs-CRP increased in current smokers (P¼0.001 and P¼0.029, respectively), although there was not an increase in the NOx level. The prevalence of a high eGFR increased in light smokers (odds ratio (OR) 1.15 (95% confidence interval (CI), 0.61-2.17)) and heavy smokers (OR 2.33 (95% CI, 1.06-5.10)) when compared with non-and past smokers (P for trend¼0.024). The multivariable-adjusted mean values of the eGFR in current smokers, reported from the lowest to the highest quintiles of hs-CRP levels, were 82.1, 85.1, 86.4 and 88.5 ml per min per 1.73 m 2 (P for trend¼0.027). The mean values of proteinuria were 28.6, 34.6, 37.2 and 39.5 mg g À1 creatinine (P for trend¼0.003). The correlation coefficient between hs-CRP and eGFR was increased significantly (P¼0.03) across non-(r¼0.03), past (r¼À0.17), light (r¼0.13) and heavy smokers (r¼0.31). In conclusion, cigarette smoking is a risk factor for renal function alteration in healthy smokers and is characterized by a high eGFR and a high urinary protein associated with an increase in the hs-CRP. This finding suggests that hs-CRP may help mediate the alteration of renal function in smokers.
INTRODUCTION
Unhealthy lifestyles are presumed to oxidatively or nitrosatively modify cellular constituents, even in the 'preclinical stages of disease,' in biological systems. 1, 2 The measurement of biomarkers of reactive species in biological samples has been suggested to be useful in predicting early disease development in healthy people. 3, 4 Cigarette smoking has been identified as an important risk factor in the promotion and progression of renal dysfunction, not only in subjects with pre-existent primary renal disease, hypertension and diabetes, [5] [6] [7] but also in healthy subjects. [8] [9] [10] Some investigations have raised hypotheses regarding the mechanisms of smoking-induced renal dysfunction, in which nonhemodynamic mechanisms are suggested to be involved in sequential steps of renal glomerulosclerosis and/or atherosclerosis. 8 Endothelial dysfunction occurs early in renal glomerulosclerosis and/or atherosclerosis and is manifested by an increase in the reactive oxygen species, an elevation of inflammatory factors 11 or a decrease in the nitric oxide (NO) level. 8, 12 Many studies suggest that cigarette smoking is associated with an augmented progression of renal dysfunction among patients with primary renal disease, hypertension and diabetes, [5] [6] [7] and that increases in both oxidative stress and inflammation may mediate renal dysfunction in hypertensive subjects. 13 This finding raises a question as to whether similar conditions might arise in healthy subjects who smoke, as to the best of our knowledge, no published research has used oxidative stress and inflammatory markers to assess the mechanism by which cigarette smoking induces progressive renal dysfunction in the general population.
Cigarette smoke contains abundant reactive oxygen species; the particulate (tar) phase of cigarette smoke contains 410 17 free radicals per g, and the gas phase contains 410 15 free radicals per puff. 14 One of the most tested and generally evaluated biomarkers of systemic oxidative stress is 8-iso-prostaglandin F 2a (8-iso-PGF2a), which is the major urinary metabolite of the F 2 -isoprostane series. 15 C-reactive protein (CRP) is a circulating pentraxin that has a major role in the human innate immune response. Highly sensitive CRP (hs-CRP) is considered to be a stable plasma biomarker for low-grade systemic inflammation. 16 Although CRP is produced predominantly in the liver, it is also expressed in smooth muscle cells and has a central role in all phases of the atherosclerotic process. 1, 16, 17 NO, the mediator of endothelium-dependent relaxation, is produced by the oxidation of L-arginine in an enzymatic reaction catalyzed by nitric oxide synthase. Although the measurement of NO itself cannot be performed, nitrite (NO 2 À ) and nitrate (NO 3 À ) (NOx) are commonly used as an index of systemic NO formation in many studies, based on the finding that NOx is the main stable metabolite. 18 This study is the first attempt to employ an ozone-based chemiluminescence assay for detecting plasma NOx in a large, healthy population.
As for the assessment of renal function, we calculated the estimated glomerular filtration rate (eGFR), measured protein urine, serum creatinine (Cre), blood urea nitrogen and uric acid. Because the GFR estimation is limited by differences in Cre generation among ethnicities, we calculated eGFR using an equation specific to the Japanese that was recently released by the Japanese Society of Nephrology. 19 We hypothesized that 8-iso-PGF2a, hs-CRP, and/or NO probably contribute to the mediation of renal function alteration in smokers. We therefore investigated the cross-sectional associations between smoking-related markers (8-iso-PGF2a, CRP and NOx) and eGFR and proteinuria in the general population, while considering the effect of potential confounders, such as lifestyle choices.
METHODS

Study design
A cross-sectional study on the relationship between oxidative/nitrosative biomarkers and lifestyle-related disease was designed within the framework of a laboratory and field study. We performed health examinations and surveys of 847 Japanese individuals from September to December 2007. All subjects were instructed to fast overnight and refrain from smoking beginning at least 10 h before the sample collection. The ethics committee of Okayama University approved the study, and written informed consent was obtained from each subject before participation.
Collection of samples
Venous blood samples were collected after overnight fasting. Serum and plasma were preserved at À80 1C until analysis. Some of the biochemical parameters of the blood samples were analyzed in Mitsubishi Chemical Medience Laboratory (Tokyo, Japan). This laboratory meets the standards of ISO 15189, the international quality management standard for laboratory testing in Japan. The blood pressure of each subject was measured by a physician with the subject in a sitting position after resting for at least a few minutes. Information on lifestyle factors was obtained through self-reporting on questionnaires. Smoking status was classified into three categories: nonsmokers, past smokers and current smokers. For subgroup analysis, current smokers were classified into two groups based on the pack-year unit: light smokers had a smoking history of o20 pack-years; and heavy smokers had a smoking history of X20 pack-years. A pack-year is equal to 20 cigarettes (1 pack), or the equivalent, smoked per day for 1 year. Alcohol consumption was converted into number of units per week. One unit was considered to be equivalent to 9-12 g of ethanol. Exercise was defined as no exercise, 1-3 times per week or more than 4 times per week.
Exclusion criteria included a history of cancer, stroke, diabetes, hypertension, ischemic heart disease, hepatitis or asthma. We also excluded women who were pregnant, breast-feeding or menstruating. Data from a total of 649 volunteers (age 18-67 years) were ultimately analyzed.
Analysis of oxidative/nitrosative stress and inflammation biomarkers
Urinary 8-iso-PGF2a level was determined by analyzing spot urine samples stored at À80 1C before analysis, using a commercially available competitive enzyme immunoassay (EIA) kit (Cayman Chemical, Ann Arbor, MI, USA). The samples were corrected for Cre excretion. Helmersson and Basu 20 reported that urinary F 2 -isoprostanes isomer levels in spot urine samples showed no significant variation from levels measured in 24-h urine samples in the same healthy individuals by radioimmunoassay. hs-CRP level was determined using a latex particle-enhanced immunoassay with the nephelometry method. The assay was able to detect 0.004-0.500 mg per 100 ml of CRP.
NO level was determined using an ozone-based chemiluminescence assay. 21 We used a freshly prepared reductive chemical, triiodide (I 3 À ), as described in a previous study. 22 To minimize protein foaming, 100 ml of 1:30 diluted silicon emulsion was added. The reduction of NO 3 À to NO 2 À was performed by incubation with 25 mU NO 3 À reductase enzyme (EC 1.7.1.2, Sigma, Tokyo, Japan) solution mixed with 0.012 mmol of the cofactor b-nicotinamide adenine dinucleotide phosphate. A standard curve relating the luminescence produced was constructed by injecting freshly prepared commercial NO 3 À standard solution (WAKO, Osaka, Japan) into NO analyzer (Sievers, NOA280i, Boulder, CO, USA). Plasma was prepared in a similar manner with standard solution. To ensure accurate analysis, we took care in sample collection, minimized light exposure and used distilled water with no NO 2 À content (Otsuka Pharmaceutical, Tokyo, Japan).
Measurement of renal function
We calculated eGFR using an equation specific to the Japanese population that was recently released by the Japanese Society of Nephrology: 19 eGFR ¼ 194Âserum Cre À1:094 Âage À0:287 ðÂ0:739 if femaleÞ
The serum Cre and uric acid levels were measured enzymatically, whereas the Bradford method (Bio-Rad Protein Assay Kit, Bio-Rad, Hercules, CA, USA) with bovine serum albumin (BSA) as a calibrator was used to measure the urinary protein content. Briefly, in a 96-well plate, the protein calibrator (10 ml of bovine serum albumin 0, 31.25, 62.5, 125, 250 and 500 mg ml À1 ) or 10ml urine were mixed with 200ml of protein assay solution diluted with four volumes of ultrapure water. After 5 min, we measured the absorbance of the assay mixture at 595 nm using a microplate reader (Molecular Devices VersaMax, Sunnyvale, CA, USA). The urine Cre concentration was determined in single spot urine samples using creatinine test kits (R&D Systems, Minneapolis, MN, USA). Urinary protein was defined as the urine protein/Cre ratio (mg g À1 ).
The blood urea nitrogen level was determined using the urease-indophenol method (WAKO), in which urea is hydrolyzed by urease to produce ammonia and CO 2 (WAKO). The ammonia reacts with the salicylate and hypochlorite in the presence of the catalyst nitroprusside to form a green indophenol in alkaline solution. The amount of urea nitrogen in the sample was determined by measuring the absorbance at 570 nm.
Statistical analysis
After the outliers were excluded, we transformed the skewed distributed variables (body mass index, NOx, 8-iso-PGF2a, hs-CRP, triglyceride, glucose, aspartate aminotransferase, g-glutamyl transpeptidase and protein urine) into log 10 format. The data were expressed as a percentage, the arithmetic mean (antilog for log 10 -transformed data)±s.d./s.e. or an odds ratio (OR) (95% CI). Because the differences between the smoking groups in terms of the biochemical parameters could have been confounded by age, sex and body mass index, we analyzed our data using analysis of covariance by adjusting for those potential confounders. After conducting multicollinearity diagnostics among Markers of smoking-induced renal function alteration R Sauriasari et al the independent variables, we performed a binomial logistic regression analysis to evaluate the independent relationship between smoking with eGFR and smoking with markers. The test for a linear trend across mean values and ORs of hs-CRP quartiles, 8-iso-PGF2a quartiles or smoking status was conducted by means of orthogonal polynomial contrast. Bivariate correlations between renal function parameters with markers, while controlling other variables, were determined using partial correlation. For comparing the correlation coefficient (r), we transformed r with the Fisher-z transform equation to the Z-score.
We then calculated a Z-score of the differences between the correlations to determine the level of significance as follows: 23
where r¼correlation coefficient and n¼number of subjects. Data analyses were performed using SPSS software (SPSS, Chicago, IL, USA; Version 12). A value of Po0.05 was considered to be statistically significant.
RESULTS
This study population included 290 men and 359 women (18-67 years old). Table 1 shows the mean urinary 8-iso-PGF2a to be 0.7 ± 2.1 ng mg À1 Cre in men and 0.5 ± 2.5 ng mg À1 Cre in women. The intra-and inter-assay repeatability (percent coefficient of variation) were 5.4 and 11.0%, respectively. The mean of the hs-CRP level was 0.06 ± 0.08 mg per 100 ml in men and 0.05 ± 0.08 mg per 100 ml in women. The NO 3 À standard slope was y¼1.60xÀ18.13 (r 2 ¼0.9974), and the mean plasma NOx concentration was 27.5 ± 1.6 mmol l À1 in men and 24.0 ± 1.6 mmol l À1 in women. The intra-and inter-assay repeatability over 2 months were 3.5 and 6.1%, respectively. These values are very similar to or within the range of many other population studied. 24, 25 A high eGFR was defined as in the upper 20% or the highest quintile (X96.7 ml per min per 1.73 m 2 ), and, similarly, high urinary protein was defined as the highest quintile (X49.4 mg g À1 Cre).
As Table 2 shows, the age, sex and body mass index adjusted mean values of 8-iso-PGF2a and hs-CRP were significantly increased in current smokers in comparison with non-and past smokers (0.7 ± 1.07 vs. 0.5 ± 1.04 and 0.5 ± 1.12 ng mg À1 Cre for 8-iso-PGF2a; 0.07 ± 0.006 vs. 0.05 ± 0.004 and 0.04 ± 0.010 mg per 100 ml for hs-CRP). However, the NOx level did not differ among the smoking groups. The urinary protein content was higher in current smokers (37.0 ± 1.04 vs. 35.5 ± 1.02 and 31.1 ± 1.06 mg g À1 Cre), whereas the serum Cre decreased significantly (0.70±0.008 vs. 0.72±0.005 and 0.73±0.013 mg per 100 ml). Moreover, smokers showed significant changes in the systolic blood pressure, diastolic blood pressure and blood profile (total protein, white blood cell and hemoglobin), in addition to increased g-glutamyl transpeptidase and triglycerides.
A logistic regression analysis with adjustment for demographic, physical and clinical variables showed that the prevalence of a high eGFR increased in current smokers in a dose-dependent manner (OR¼1.24 (95% CI, 0.66-2.31) for light smokers; OR¼2.68 (95% CI, 1.27-5.66) for heavy smokers (P for trend 0.006)). Adjusting for lifestyle variables (alcohol consumption and exercise) further attenuated the prevalence of a high eGFR, and the OR was still found to be significant (OR¼1.14 (95% CI, 0.61-2.15) for light smokers; OR¼2.33 (95% CI, 1.07-5.11) for heavy smokers (P for trend 0.024)) ( Table 3 ).
As Table 4 shows, the mean values and ORs of high eGFR according to 8-iso-PGF2a quartiles were significant for nonsmokers, but not for current smokers. On the other hand, the increase in the hs-CRP level was in parallel with the increase of eGFR and the urinary protein level, which was observed only in current smokers, but not in nonsmokers ( Table 5 ). The mean values from the lowest to highest quartile of hs-CRP in current smokers were 82.1, 85.2, 86.4 and 88.5 for eGFR (P for trend¼0.027) and 28.6, 34.6, 37.2 and 39.5 for urinary protein (P for trend¼0.003). Meanwhile, the prevalence of a high eGFR also increased with an increase in the hs-CRP levels. We did not show data of past smokers because there was not a prevalence of a high eGFR for some groups in the hs-CRP and 8-isoprostane quartiles of past smokers.
After conducting a partial correlation test, we found that the eGFR of current smokers was positively correlated with hs-CRP (r¼0.16, P¼0.033). When the group of current smokers was stratified to light and heavy smokers, the Fisher-z transformation test showed a significant increase (P¼0.032) across non-(r¼0.03), past (r¼À0.17), light (r¼0.13) and heavy smokers (r¼0.31). Testing to determine whether one correlation coefficient is higher than another showed that the correlation between hs-CRP and eGFR in heavy smokers was higher than nonsmokers (P¼0.023) and past smokers (P¼0.008) (Figure 1) .
DISCUSSION
This study demonstrates that cigarette smokers have an alteration in renal function characterized by a higher eGFR/hyperfiltration and higher urinary protein levels, which is consistent with other studies conducted in humans 9, 26 and animals. 27 Previously, Pinto-Sietsma et al. 28 demonstrated a relationship between smoking and either an increased or decreased GFR in the same population. On the other hand, some studies reported contradictory findings that cigarette smoking reduced GFR. 29, 30 It was suggested by Yoon et al. 9 that smoking is associated with an increase in eGFR, although a different impact might be presented for a small subset of the population who were more susceptible to a decrease in eGFR.
Two previous studies did not take other lifestyle factors (alcohol consumption and exercise) into account, 9,26 but our study showed that these two factors confounded the results. An increasing alcohol consumption 31 and intensity of daily physical exercise 32 correlated with the increase of GFR. However, smoking strongly and independently increased eGFR because the significance persists even after controlling for alcohol consumption and exercise. Evidence of thickening of the walls of the renal arterioles and small arteries after nicotine abuse has been found during autopsies of patients with renal disease 33 and subjects without known renal or vascular disease. 34 Moreover, animal experimental evidence indicates that cigarette smoking enhanced the permeability of the endothelial monolayers 35 and an elevation of intraglomerular capillary pressure, which is associated with an elevated GFR. It was reported that there is an association between an elevated GFR and a high-normal albuminuria in the nondiabetic population. 36 Many other studies also have documented an increased risk of proteinuria in smokers. 9, 10, 26, 28 Here we observed that current smokers have a higher urinary protein level than non-and past smokers. Certain drugs, such as angiotensin II receptor blockers, may affect the amount of urinary protein excretion. However, our study subjects are an apparently healthy population who do not consume any other medications, including angiotensin II receptor blockers.
The mechanism of this higher renal function in current smokers is still unknown. It was hypothesized that cigarette smoke eventually causes renal vasodilation, leading to chronic glomerular hyperfiltration mediated by an increased urinary cyclic guanosine monophosphate, and release of NO and atrial natriuretic peptide. 10 However, the plasma NOx concentration was not associated with smoking status in our present study population. In vitro and in vivo studies showed a reduction of NO after cigarette smoking exposure. [37] [38] [39] However, the majority of in vitro data has involved the use of cigarette smoke extract solution, which is probably not an appropriate physiological model, as circulating particulate of cigarette smoke has to first bypass the lung. 40 Thus, the effect of smoking on the NO pathway seems to be more complex on a cellular level than suggested by the described Abbreviations: ALT, alanine transaminase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; g-GTP, g-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL-c, high-density lipoprotein-cholesterol; HOMA, homeostatic model assessment; LDL-c, low-density lipoprotein-cholesterol; NS, nonsignificant. Data are shown as mean ± s.e. Skewed data were log 10 -transformed and presented as mean value converted into exponential age, sex and BMI adjusted. eGFR¼194Cr À1.094 Âage À0.287 Â0.739 (if female).
mechanisms. 41 Recent clinical epidemiological studies in humans showed that the plasma NOx level was a little higher in smokers than in nonsmokers. 25, 42 However, the difference was no longer significant after correction for some important clinical variables. 42 Moreover, Barua et al. 40 and Rångemark and Wennmalm 43 reported no differences in the NOx level among smoking groups, which is similar to our findings. 39, 43 Cigarette smoking generates O 2 ÁÀ which contributes to the catalysis of arachidonic acid peroxidation to F 2 -isoprostanes, leading to a high level of F 2 -isoprostanes in smokers, as shown in this study and other studies. 44 , 45 We did not find a correlation between 8-iso-PGF2a and either the eGFR or urinary protein in apparently healthy smokers. On the other hand, we detected a positive association between the eGFR and 8-iso-PGF2a only in nonsmokers, although the significance was not present in current smokers. These results indicate that smoking may influence the association between eGFR and 8-iso-PGF2a.
In contrast, we demonstrated a significant association between the hs-CRP and a high eGFR and high urinary protein in current smokers, which was not seen in nonsmokers. Cigarette smoking is known to increase the expression of inflammatory markers, including CRP. 11, 46 This finding indicates that hs-CRP was increased by smoking, and its association with the eGFR and urinary protein was strongly modified by cigarette smoking.
There is an association between proteinuria and vascular permeability, because capillary fluid permeability and transvascular albumin leakage increased in otherwise healthy patients with proteinuria. 47 One possible mechanism of this increased vascular permeability is endothelial dysfunction. 47 Given that systemic inflammation at a lowgrade level is held partly responsible for the modulation of vascular permeability, 47 it is plausible that an elevated CRP derived from cigarette smoking may directly alter renal vascular permeability, and thus be causally involved in the hyperfiltration of remnant glomeruli, resulting in the development of proteinuria. This hyperfiltration, together with the transvascular albumin leakage, could result in further glomerular damage. The strengths of our study include the population-based samples, the measurement of all clinical variables and biomarkers at a single laboratory using the same evaluation protocols, and the availability of information on potential confounding factors. We measured GFR using a newly derived Cre-based GFR-estimating equation, which Figure 1 Scatter plot for the correlation between estimated glomerular filtration rate (eGFR) and highly sensitive C-reactive protein (hs-CRP), stratified by smoking status. Adjusted r was adjusted for age, sex and body mass index. a P¼0.023 compared with nonsmokers, b P¼0.008 compared with past smokers.
Markers of smoking-induced renal function alteration R Sauriasari et al provided reasonably more accurate and specific eGFR for Japanese individuals. 19 Moreover, we used a hs-CRP assay, which has high analytical precision. The increased variance of our CRP data yields greater statistical power to detect small, but nonetheless important associations. Potential limitations of this study include a single ethnic origin of participants, which might limit the generalization of the results. The cross-sectional nature of study design also could hardly determine a causal relation between smoking and renal dysfunction. We also could not exclude other potential confounders, such as NO 2
